DeCure for Chronic lymphocytic leukemia/small lymphocytic lymphoma
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for chronic lymphocytic leukemia/small lymphocytic lymphoma — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChronic lymphocytic leukemia/small lymphocytic lymphoma maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for chronic lymphocytic leukemia/small lymphocytic lymphoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
notch receptor 1 (NOTCH1) — NOTCH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6PY8 · 3.75 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Chronic lymphocytic leukaemia and small lymphocytic lymphoma are now understood to be two manifestations of the same disorder, with the cell of origin being a mature B lymphocyte that carries a rearranged immunoglobulin gene. The disease is the most prevalent lymphoid neoplasm in Europe and North America. CLL cells express only modest amounts of surface immunoglobulin and are characterised by defective apoptosis; the cause remains unknown.
A 1979 report described two patients with pre-existing chronic lymphocytic leukaemia who developed a second lymphoproliferative disorder — either histiocytic lymphoma or Hodgkin disease — which had previously been considered a terminal event. Both patients achieved an objective clinical response after their therapy was changed to a more aggressive combination of drugs. The authors concluded that any sudden change in the clinical course of a CLL patient should prompt a thorough reevaluation for a second lymphoproliferative disorder, and that if one is found, more aggressive therapy should be initiated.
A 2020 case report described a patient diagnosed with stage IV small lymphocytic lymphoma who presented to the emergency room with acute neurologic manifestations, specifically unilateral vision loss. No treatment outcome or survival data were provided for that patient.
No randomised trial has established a standard repurposed drug for CLL or SLL. What is missing is a prospective, controlled study that stratifies patients by genetic subtype and prior treatment history, and that is adequately funded to test a specific repurposed agent against current standard care.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Oxford University Press eBooks · 2010 · 5 citations
Chronic lymphocytic leukaemia
AbstractChronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL) is the most prevalent lymphoid neoplasm in Europe and North America. The ‘cell of origin’ is a mature B lymphocyte that has a rearranged immunoglobulin gene. CLL cells express modest amounts of surface immunoglobulin, and are characterized by defective apoptosis. The cause of CLL is unknown....
Medical and Pediatric Oncology · 1979 · 1 citations
Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: Response to chemotherapy in two cases
AbstractThe development of either histiocytic lymphoma or Hodgkin disease in association with pre-existing chronic lymphocytic leukemia has been described in the literature as a terminal event. We describe two patients in whom the diagnosis of a second malignant lymphoma was made during life and who achieved objective clinical response after a change in therapy to a more aggressive combination of drugs. We conclude that patients with chronic lymphocytic leukemia who have had a sudden change in their clinical course should have thorough reevaluation, looking specifically for the development of a second lymphoproliferative disorder. If this is discovered, more aggressive therapy should be initiated.
Cambridge University Press eBooks · 2001 · 0 citations
Small lymphocytic lymphoma and its variants
AbstractSmall lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL) are in the midst of a period of huge change due to advances on several fronts. One important development is the appreciation that SLL and CLL are two manifestations of the same disorder. Throughout this review, therefore, it should be assumed that SLL is managed in a similar manner to CLL, though the studies drawn upon and recommendations made will be based mainly on publications on the diagnosis and therapy for CLL.
Case Reports in Oncological Medicine · 2020 · 0 citations · open access
Stage IV Small Lymphocytic Lymphoma Presenting with Unilateral Vision Loss
AbstractSmall lymphocytic lymphoma (SLL) is a manifestation of chronic lymphocytic leukemia (CLL) in which malignant B-cell lymphocytes accumulate in the lymph nodes or bone marrow. In this report, we describe the medical course of a patient diagnosed with stage IV small cell lymphocytic lymphoma, who presented to the emergency room with acute neurologic manifestations of SLL.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
